Scarica l'app Stockscreener
197.74
2.67%
-5.42
Dopo l'orario di chiusura:
199.57
1.83
+0.93%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BIIB Giù?
Forum
Previsione
Frazionamento azionario
Biogen Inc Borsa (BIIB) Ultime notizie
Biogen stock trades steady as revenue growth and Alzheimer’s portfolio shape outlook - Ad-hoc-news.de
Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Former Biogen Executive to Lead Research at Formation Bio - Bloomberg.com
Biogen And The Limitation Of The Tau Approach To Alzheimer's Disease - Seeking Alpha
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Total liabilities & shareholders' equities of Biogen Inc. – BCS:BIIB1 - TradingView
Discontinued operations of Biogen Inc. – BCS:BIIB0 - TradingView
BofA Securities Adjusts Biogen Price Target to $215 From $217 - marketscreener.com
Guggenheim Adjusts Price Target on Biogen to $280 From $260, Maintains Buy Rating - marketscreener.com
BofA cuts Biogen stock price target on higher expectations bar - Investing.com
BofA cuts Biogen stock price target on higher expectations bar By Investing.com - Investing.com Canada
Biogen stock steadies as Alzheimer’s launch and pipeline guide long-term growth - Ad-hoc-news.de
Biogen (BIIB) Expands Its Alzheimer’s Pipeline, Is The 9% Undervaluation Still There? - simplywall.st
FDA 'Gets to Pick the Jury': Steve Uden on Biogen's Tau Gamble and a UK Political Reset - finance.biggo.com
U.K. cabinet shuffle, Taiwan biotech and Biogen data — a BioCentury podcast - biocentury.com
Biogen Inc. stock underperforms Monday when compared to competitors - MarketWatch
Biogen Brings On Spur Therapeutics CEO As Legal Chief - Law360
Goldman Sachs Adjusts Price Target on Biogen to $271 From $250, Maintains Buy Rating - marketscreener.com
Biogen stock edges higher as Alzheimer’s and neuromuscular pipeline shapes outlook - ad-hoc-news.de
Biogen stock trades steady as Alzheimer’s revenue and pipeline shape valuation - ad-hoc-news.de
Biogen’s mixed Alzheimer’s data; Two new startups launch; and more - Endpoints News
Biogen Inc. stock underperforms Friday when compared to competitors - MarketWatch
Bronstein, Gewirtz & Grossman, LLC Is Investigating Biogen Inc. (BIIB) And Encourages Stockholders to Connect - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Will AbbVie's Neuroscience Franchise Deliver Another Strong Quarter? - TradingView
Biogen Taps Biopharmaceutical Veteran as Chief Legal Officer - Bloomberg Law News
Biogen moves forward with Alzheimer's drug candidate following phase 2 study - medwatch.com
Tens of Thousands With Ataxias Can Access Virtual Care - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Is Investigating Biogen Inc. (BIIB) And Encourages Shareholders to Connect - The National Law Review
Rx Rundown: Biogen, Neko Health, Roche and more - Medical Marketing and Media
Is Biogen (BIIB) a Buy, Hold, or Sell Right Now - Kavout | AI
Biogen shares slide as diranersen data raise dosing question - The Pharma Letter
Roche/ Biogen kidney drug granted FDA priority review for label expansion - Seeking Alpha
Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider - GlobeNewswire Inc.
Biogen Shares Decline After Detailed Diranersen Alzheimer's Study Data - Yahoo Finance
Biogen names Michael Parini as chief legal officer - Investing.com
Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Biogen (BIIB) and Cadrenal Therapeutics, Inc. (CVKD) - The Globe and Mail
Biogen names Michael Parini as chief legal officer By Investing.com - Investing.com Canada
Biogen Appoints Michael J. Parini as Chief Legal Officer - Biogen
Biogen's incoming legal chief has 20 years in biotech leadership - Stock Titan
Form S-1 Biogen Inc For: 15 July By Investing.com - Investing.com Nigeria
AAIC26: Biogen stock drops after unveiling tau-targeting ASO data - Clinical Trials Arena
Tau In The Clinic, Again - Seeking Alpha
Biogen (BIIB) Is Down 6.7% After At-Home LEQEMBI Launch And New Alzheimer’s DataHas The Bull Case Changed? - simplywall.st
Anti-Tau Agent Diranersen Slows Cognitive Decline Across Multiple Endpoints in Phase 2 CELIA Trial, Biogen to Advance to Phase 3 - NeurologyLive
Biogen stock holds steady as Alzheimer portfolio and pipeline shape the long-term story - Ad-hoc-news.de
Biogen (BIIB) Following Fresh Alzheimer’s Data Is The Upside Story Still Intact - Yahoo Finance
Biogen Inc. (BIIB) Presents at Alzheimer's Association International Conference (AAIC Meeting) 2026Slideshow - Seeking Alpha
Biogen Inc (BIIB) Shares Fall 8.2% -- What GF Score of 74 Tells Investors - GuruFocus
Biogen Inc.'s Stock Price Plummets to $191.95, Recording a Sharp 8.17% DropThe Latest Market Update - Smartkarma
Biogen (BIIB) Alzheimer’s Association International Conference (AAIC Meeting) 2026 summary - Quartr
Biogen Backs Alzheimer’s Tau Drug for Phase 3 Despite Trial Miss - Yahoo Finance
BIIB Stock On Track For Worst Day In 2 Years After RBC Questions If Alzheimer’s Drug Benefits Will Replicate In Further Study - Stocktwits
An experimental Alzheimer's drug shows some promise as researchers hunt new approaches - Los Angeles Times
Biogen (BIIB) Shares Face Scrutiny After CELIA Study Results - GuruFocus
Biogen (BIIB) Receives Mixed Feedback on CELIA Study Data - GuruFocus
Biogen’s Alzheimer’s Drug Leaves Questions Unanswered, and That’s a Problem - Barron's
Biogen at aaic 2026: tau drug advances despite mixed trial readout - Investing.com
IBM, Goldman Sachs, SK Hynix, Micron, CrowdStrike, Biogen, and More Stocks That Explain Today's Market -- Barrons.com - Moomoo
Biogen's Alzheimer's drug lowers toxic protein, but results were mixed - Reuters
Biogen (BIIB) Reports Mixed Results on Alzheimer's Drug Diraners - GuruFocus
Biogen Stock Falls After Lackluster Trial Data for Alzheimer's Drug Targeting Tau - Briefs Finance
Biogen Wins FDA Approval for Subcutaneous Starter Dose of Leqembi - Yahoo Finance
Biogen Inc at Alzheimer's Association International Conference (AAIC) Transcript - GuruFocus
Why Is Biogen Stock Falling Tuesday? - Benzinga
Eisai, Biogen report real-world Alzheimer’s drug study results - Investing.com
Biogen tumbles 8.7% as breakthrough Alzheimer’s data is clouded by dosing paradox - Investing.com South Africa
LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment - Biogen
Biogen drops after data for novel Alzheimer’s drug (BIIB:NASDAQ) - Seeking Alpha
Nearly 87% of Alzheimer's Patients Chose to Stay on LEQEMBI - Stock Titan
Biogen Drops 7.7% After Morgan Stanley Maintains Equal-Weight - AlphaStreet
0.48%
0.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):